As “Breakthrough Therapy” Designations Rise, So Do Disclosure Questions

With FDA prohibited from disclosing information about products in development, sponsors must decide whether to announce if the agency has granted or denied a designation request. Communications are particularly challenging for small companies, for whom a denial might be a material event.